---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-223699"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2022-08-18T23:59:59+00:00"
generated_at: "2026-06-23T22:43:03.323518+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA lifts partial clinical hold on Curis's TakeAim Lymphoma study of emavusertib

## Summary
- FDA lifted partial clinical hold on TakeAim Lymphoma Phase 1/2 study; enrollment to resume Q3 2022.
- Partial hold on TakeAim Leukemia study remains under FDA Division of Hematologic Malignancies 1.
- Hold lifted after FDA agreement on rhabdomyolysis management and enrollment of ≥9 patients at 200 mg emavusertib plus ibrutinib.
- Preliminary clinical data update from TakeAim Lymphoma expected in 2023.

## SEC filing metadata
- accession: 0001193125-22-223699
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2022-08-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000119312522223699/0001193125-22-223699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000119312522223699/d356879d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-223699
- JSON: https://secwatch.observer/filing/0001193125-22-223699.json
- Plain text: https://secwatch.observer/filing/0001193125-22-223699.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.